

PRESS RELEASE

Schülke & Mayr GmbH acquires Spanish company Vesimin Health

- This strategic acquisition will allow Schülke to create synergies between its R&D and Supply areas, as well as strengthen its presence and product portfolio in southern Europe within the framework of an ambitious expansion plan being carried out by the German group.
- Vesimin -which will continue as an independent company within the group, maintaining its entire human team- will expand its portfolio of innovative disinfection solutions, promote its own R&D&i, and accelerate its national and international growth.
- The companies also plan to create an R&D a center of excellence for chlorhexidine-based products, in the light of experience of Vesimin, which was a pioneer in Spain in formulating and launching this antiseptic substance on the market, which today is on the list of WHO Essential Medicines.
- Schülke has been a global leader in infection prevention and hygiene control for more than 130 years. The German group already has more than 1,100 dedicated employees, over 20 subsidiaries and three production sites, in Germany, France, and Brazil. People in more than 80 countries around the world rely on Schülke's infection prevention and hygiene solutions every day.
- Vesimin was founded in 2004 by entrepreneur Víctor Vallés as a project incubated at IQS University Center to face healthcare-associated infections (HAIs) by providing effective and innovative solutions. The company has seen double-digit growth, with average annual growth (CAGR) of 27% for the past 5 years. Its turnover for 2021 was nearly €12 million, 30% of which was from exports to 45 countries. Vesimin is currently present at over 400 hospitals in Spain and expanding into other markets, like pharmaceuticals and veterinary.

Barcelona, 12 September 2022. [Schülke & Mayr GmbH](#), a leading global provider in the fields of infection prevention and hygiene solutions in healthcare, acquires [Vesimin Health](#), based in the [Barcelona Science Park](#).

Vesimin Health's mission – which is a perfect match to the Schülke mission 'we protect lives worldwide' – is to develop and promote innovative disinfectants, with a proven specialization in hospital infection control. The company provides market-leading chlorhexidine-based antiseptics, surface disinfectants, high-level disinfection solutions for medical devices and equipment based on the most advanced technologies. With this strategic acquisition, Schülke strengthens its presence in Southern Europe – primarily Spain, France, Portugal – and creates synergies in the areas of R&D and Sourcing and perfectly complements portfolio of Schülke.

Vesimin Health also offers with [Vesimin UV](#) a technology that provides advanced disinfection with ultraviolet light, designed to achieve high efficiency in hospital disinfection.

Schülke already has more than 1,100 dedicated employees, over 20 subsidiaries and three production sites in Germany (Schülke), France (Bioxal) and Brazil (Vic Pharma). People in more than 80 countries around the world rely on Schülke's infection prevention and hygiene solutions every day. Following the acquisition of the Danish company Wet Wipe A/S in early July 2022 and the associated expansion into the Scandinavian market, Schülke is now further extending its reach as well as its product portfolio in Southern Europe.

Stefan Kukacka, CEO of Schülke, explains: *"The acquisition once again underlines our ambitious growth strategy and our mission 'to protect lives worldwide'. With Vesismín Health, we are expanding the Schülke Group with a high-profile company for infection prevention and hygiene solutions in healthcare. Based on Vesismín Health's expertise in formulations with the active ingredient chlorhexidine, we will together create a center of excellence for chlorhexidine-based products. We are very much looking forward to working together and sharing our experiences and joint innovations!"*

Víctor Vallés, Founder and CEO of Vesismín Health: *"We are very pleased to become part of the Schülke Group, which has long-standing experience as a global supplier in the field of infection prevention and hygiene solutions. This union strengthens our position, broadens our current product range, and turns us into the supplier with the most extensive range of infection prevention products. The agreement with the Schülke Group will permit us to further develop our expertise in chlorhexidine-based products, as well as to continue to maintain our profile as an innovative company. Vesismín Health will continue as an independent company within the group and will maintain its current team of professionals. This collaboration will allow us to grow both in the Spanish market and in other markets and to take another step forward in our commitment and our raison d'être: the daily fight against hospital-acquired infections."*

■ Schülke & Mayr

Schülke & Mayr GmbH has been a global leader in infection prevention and hygiene control for more than 130 years. With its wide range of high-quality and innovative products, expert advice, and reliable service, Schülke offers holistic concepts for infection prevention in professional healthcare markets, consumers and in the pharmaceutical sector. Committed to our mission of protecting lives worldwide, we actively contribute to the safety and protection of human health in our strategic business areas of healthcare.

Over the Counter (OTC) and Industrial Hygiene. Infectious agents know no borders - this is gaining even more importance in today's globalized world. Schülke is present with more than 1,100 dedicated employees, over 20 subsidiaries and three production sites in Germany (Schülke), France (Bioxal) and Brazil (Vic Pharma). People in more than 80 countries around the world rely on our products every day.

■ About Vesismín Health

Vesismín Health was founded in Barcelona in 2004 as a project within the **IQS** university center by entrepreneur Víctor Vallés. Since then, the company's main goal is the close collaboration with healthcare centres in their fight to face HAI by providing effective, innovative disinfection solutions.

Among other challenges achieved, Vesismín Health was a pioneer in introducing and changing the habits of healthcare professionals regarding single-use wipes, both for disinfecting skin and instruments, making disinfection easier and more hygienic. The company was also the first laboratory to formulate and launch orange chlorhexidine, in 2012, as an alternative to povidone-iodine to facilitate antisepsis of the surgical field and reduce infections,

The company has seen double-digit growth, with average annual growth (CAGR) of 27% for the past 5 years. Its turnover for 2021 was nearly €12 million, 30% of which was from exports to 45 countries, including France, Poland, the United States, the United Kingdom, China, Romania, and the Dominican Republic, among others. They also kicked off a plan to attract talent, which increased their team by 29%. The company is currently present at over 400 hospitals in Spain and expanding into other markets, like pharmaceuticals and veterinary.